Petros Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $135.07K
- P/E (TTM)
- –
- Dividend yield
- –
About Petros Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Petros Pharmaceuticals, Inc. operates as a healthcare technology company focused on expanding consumer access to nonprescription pharmaceuticals. The company develops a proprietary integrated technology solutions platform designed to assist pharmaceutical companies in transitioning prescription drugs to over-the-counter status under regulatory frameworks for nonprescription drug products with an additional condition for nonprescription use. Its platform consists of a software-as-a-service solution for operationalizing commercialization, data exchange, and regulatory compliance, paired with software as a medical device to provide an assistive consumer self-selection interface. Petros targets pharmaceutical label owners, direct-to-consumer self-care companies, and emerging health technology firms seeking licensable commercialization pathways.
The company operates through a virtual technology infrastructure and does not own any real property. Its principal executive offices are located in New York, New York. As of December 31, 2025, Petros Pharmaceuticals employed three full-time employees, all based in the United States.
Summary of the business section of Petros Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Petros Pharmaceuticals, Inc.
- Founded
- 2020
- Headquarters
- New York, NY
- Address
- 1185 Avenue Of The Americas, 3rd Floor 10036
- Phone
- (973) 242-0005
- Website
- petrospharma.com
- Employees
- 3, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- MARCUM LLP, Morristown, New Jersey
Stock & identifiers
- Ticker
- PTPI
- Exchange
- OTC
- Shares outstanding
- 42M, Aug 15, 2026
- Public float
- $1.44M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-25 reverse, May 1, 2025; 1-for-25 reverse, Apr 29, 2025; 1-for-10 reverse, Dec 1, 2022; 1-for-10 reverse, Nov 30, 2022
- SEC CIK
- 1815903
- EIN
- 85-1410058
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert Weinstein | Chief Accounting Officer | 636,004 |
| Fady Boctor | See Remarks | 894,986 |
| Mitchell Arnold | See Remarks | 150,390 |
| Wayne Remell Walker | Director | 881,333 |
| Joshua Silverman | Director | 8,790,450 |
| Bruce Bernstein | Director | 3,762,334 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 3 full time employees, all of whom were based inside the United States.”
Corporate history
Events identified from SEC filings